Clinical Research Papers:
A comparison of treatment modalities for nasal extranodal natural killer/T-cell lymphoma in early stages: The efficacy of CHOP regimen based concurrent chemoradiotherapy
Metrics: PDF 1136 views | HTML 1888 views | ?
Jianzhong Cao1,*, Shengmin Lan1,*, Liuhai Shen2, Hongwei Si2, Ning Zhang1, Hongwei Li1, Ruyuan Guo1
1Department of Radiotherapy, Shanxi Cancer Hospital and Institute, Affiliated Hospital of Shanxi Medical University, Shanxi, China
2Department of Nuclear Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China
*These authors have contributed equally to this work
Hongwei Si, email: [email protected]
Keywords: nasal extranodal natural killer/T-cell lymphoma, concurrent chemoradiotherapy
Received: July 28, 2016 Accepted: November 07, 2016 Published: November 25, 2016
This study was designed to evaluate the efficacy of several treatment modalities, including CHOP based concurrent chemoradiotherapy (CCRT), for the patients with stage IE or IIE nasal extranodal NK/T-cell lymphoma (nasal ENKL). The cases were retrieved between 2000 and 2010 (n=94), and were followed to the end of February 2016. The patients were grouped into A (chemotherapy alone; CT alone), B (sequential treatment) and C (CCRT). For those with efficacy evaluation for overall treatment (n=90), CR was attained in 60.0% (18/30), 69.8% (30/43) and 76.5% (13/17) patients in the group A, B and C, respectively. The 5-year OS rate was 35.2%, 41.9% and 70.6% in the group A, B and C, respectively. For patients with early stage diseases (IE and IIE), the ECOG performance status and the Ann Arbor stage were significant prognostic factors for both OS and PFS. Among the stage IE patients, besides the ECOG performance status, three prognostic factors which related to treatments (treatment modalities, efficacy of initial and overall treatment) were significant against OS or PFS. In conclusion, compared to chemotherapy alone and sequential treatment, nasal ENKL patients in early stages, especially stage IE, benefit the most from CHOP based concurrent chemoradiotherapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.